Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28693887 | 0.86 | KDM4E (0.50) | HCAR2PDE4DKDM4EPOLBMAPT | |
| SCHEMBL3955623 | 0.83 | HCAR2 (0.65) | HCAR2PDE4DKDM4EPOLBMAPT | |
| SCHEMBL28577499 | 0.83 | KDM4E (0.48) | HCAR2PDE4DKDM4EPOLBMAPT | |
| SCHEMBL19555846 | 0.81 | HCAR2 (0.63) | HCAR2PDE4DKDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL19158730 | 0.81 | PDE4D (0.59) | HCAR2PDE4DKDM4EPOLBMAPT | |
| SCHEMBL17478828 | 0.80 | KDM4E (0.46) | HCAR2PDE4DKDM4EPOLBMAPT | |
| SCHEMBL7814443 | 0.80 | PDE4D (0.58) | HCAR2PDE4DKDM4EPOLBMAPT | |
| SCHEMBL31367819 | 0.80 | PDE4D (0.73) | PDE4DKDM4EPOLBMAPTKMT2A | |
| SCHEMBL17224898 | 0.79 | HCAR2 (0.47) | HCAR2PDE4DKDM4EPOLBMAPT | |
| SCHEMBL2846088 | 0.79 | HCAR2 (0.59) | HCAR2PDE4DKDM4EPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388601-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12358928-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2025-07-15 | — | — | US | disclosed |
| CN-118994191-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118994190-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-114437105-B | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-10-11 | — | — | CN | disclosed |
| US-20240150376-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-20230043400-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230043400-A1 | Compounds, Compositions and Methods | DENALI THERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | disclosed |
| CN-114437105-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-109071504-B | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2022-03-08 | — | — | CN | disclosed |
| WO-2017136727-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| US-9346811-B2 | 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2016-05-24 | — | — | US | disclosed |
| EP-2681219-B1 | 6,7-DIHYDRO-PYRAZOLO[1,5-A]PYRAZIN-4-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-28 | — | — | EP | disclosed |
| EP-2681219-A1 | 6,7-DIHYDRO-PYRAZOLO[1,5-A]PYRAZIN-4-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | Janssen Pharmaceutica, N.V. (BE) | 2014-01-08 | — | — | EP | disclosed |
| US-20140005200-A1 | 6,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZIN-4-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-02 | — | — | US | disclosed |
| WO-2012117027-A1 | 6,7-DIHYDRO-PYRAZOLO[1,5-A]PYRAZIN-4-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-07 | — | — | WO | disclosed |
| EP-1551403-B1 | 5-SUBSTITUTED 2H-PYRAZONE-3-CARBOXYLIC ACID DERIVATIVES AS ANTILIPOLYTIC AGENTS FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS SUCH AS DYSLIPIDEMIA | ARENA PHARM INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-20060167270-A1 | 5-substituted 2h-pyrazone-3-carbixylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia | ARENA PHARMACEUTICALS INC. (US) | 2006-07-27 | — | — | US | disclosed |
| EP-1551403-A1 | 5-SUBSTITUTED 2H-PYRAZONE-3-CARBOXYLIC ACID DERIVATIVES AS ANTILIPOLYTIC AGENTS FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS SUCH AS DYSLIPIDEMIA | Arena Pharmaceuticals, Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004032928-A1 | 5-SUBSTITUTED 2H-PYRAZONE-3-CARBOXYLIC ACID DERIVATIVES AS ANTILIPOLYTIC AGENTS FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS SUCH AS DYSLIPIDEMIA | ARENA PHARMACEUTICALS, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005200-A1 | 6,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZIN-4-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | HCAR2 3737/4885PDE4D 1198/4885KDM4E 3922/4885 |
| US-20250388601-A1 | Compounds, Compositions and Methods | AURKC, WEE2, ERBB2 | HCAR2 924/4885PDE4D 3604/4885KDM4E 2322/4885 |
| US-20240150376-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | HCAR2 3504/4885PDE4D 1288/4885KDM4E 1466/4885 |
| US-12358928-B2 | Compounds, compositions and methods | PIK3CA, PLK1, PIK3CB | HCAR2 3504/4885PDE4D 1288/4885KDM4E 1466/4885 |
| US-20060167270-A1 | 5-substituted 2h-pyrazone-3-carbixylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia | ACE, ACE2, AGTR2 | HCAR2 30/4885PDE4D 3007/4885KDM4E 2712/4885 |
| US-20230043400-A1 | Compounds, Compositions and Methods | PIK3CA, PLK1, PIK3CB | HCAR2 3504/4885PDE4D 1288/4885KDM4E 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.